Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy

BACKGROUND: According to the randomized multicenter phase II trial (ALTER1202), anlotinib has been approved as a third‐line therapy for advanced small‐cell lung cancer (SCLC). Some studies showed the predictive function of inflammatory markers, including neutrophil‐to‐lymphocyte ratio (NLR), platele...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tian, Tang, Mengqiu, Xu, Xiaoyu, Liang, Gaofeng, Xiang, Zhenfei, Lu, Yi, Wang, Chen, Shen, Weiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757002/
https://www.ncbi.nlm.nih.gov/pubmed/36441595
http://dx.doi.org/10.1002/jcla.24772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757002/
https://www.ncbi.nlm.nih.gov/pubmed/36441595
http://dx.doi.org/10.1002/jcla.24772

Ejemplares similares